641 patents currently held
115 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in Feb 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
87
Ending by 2030
Feb 2027
Next term end
468
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Aug 2029 · Medium confidence
Also notable
Ends Aug 2033 · Medium confidence
Also notable
Ends Mar 2033 · High confidence
Mif Modulators
US 11,584,717
Cited by 34 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2029. A terminal disclaimer caps this term to an earlier patent's.
System, Device and Method for High-Throughput Multi-Plexed Detection
US 9,188,586
Cited by 135 later US patents, top 5% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Intranasal Administration of Ketamine to Treat Depression
US 8,785,500
Cited by 88 later US patents, top 10% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2033.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 10 fees due Nov 16 to 30, 2026 · next Nov 16
- 6 fees due Dec 4 to 30, 2026 · next Dec 4
- 8 fees due Jan 2 to 23, 2027 · next Jan 2
- 8 fees due Feb 4 to 28, 2027 · next Feb 4
- 11 fees due Mar 3 to 26, 2027 · next Mar 3
- 23 fees due Apr 1 to 30, 2027 · next Apr 1
- 12 fees due May 5 to 28, 2027 · next May 5
- 9 fees due Jun 5 to 30, 2027 · next Jun 5
- 14 fees due Jul 2 to 30, 2027 · next Jul 2
- 13 fees due Aug 2 to 27, 2027 · next Aug 2
- 14 fees due Sep 1 to 30, 2027 · next Sep 1
- 16 fees due Oct 7 to 28, 2027 · next Oct 7
- 3 fees due Nov 10 to 12, 2027 · next Nov 10
Recent changes
- Nov 10Assignment recorded on 1 record: Hansen, James and 1 other to Yale University Recorded Nov 10, 2026, executed Nov 1, 2023. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76695, frame 648.
- Nov 6Assignment recorded on 1 record: Li, Bingjun and 3 others to Yale University Recorded Nov 6, 2026, executed Apr 10, 2025. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76658, frame 549.
- 16 of the patents on this record were granted since Aug 18, 2026
- 1 term has ended since Aug 18, 2026
What they patent
The 5 largest of its 468 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Compositions for Treating Pathological Calcification Conditions, and Methods Using Same | 9 in force | to May 2036 |
| Hyperbranched Polyglycerol-Coated Particles and Methods of Making and Using Thereof | 9 in force | to May 2035 |
| Chimeric Small Molecules for the Recruitment of Antibodies to Cancer Cells | 8 in force | to Dec 2030 |
| Nanolipogel Vehicles for Controlled Delivery of Different Pharmaceutical Agents | 6 in force | to Sep 2034 |
| Compositions and Methods for Treating Pathological Calcification and Ossification | 6 in force | to Feb 2034 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,943,130 | Methods and Compositions Relating to CCR5 Antagonist, Ifn-Gamma and IL-13 Induced Inflammation In force · High confidence | In force | High confidence | |
| US 7,985,538 | Drug Resistance and Methods of Reversing In force · High confidence | In force | High confidence | |
| US 9,539,220 | Methods for Treating Suicidal Ideation held by The United States Government as Represented by the Department of Veterans Affairs and Yale University In force · High confidence | In force | High confidence | |
| US 9,592,207 | Intranasal Administration of Ketamine to Treat Depression held by The United States Government as Represented by the Department of Veterans Affairs and Yale University In force · High confidence | In force | High confidence | |
| US 10,765,739 | Use of Mif and Mif Pathway Agonists In force · High confidence | In force | High confidence | |
| US 8,008,262 | Beta-Peptides In force · High confidence | In force | High confidence | |
| US 7,835,076 | Optical System for Illumination of an Evanescent Field In force · High confidence | In force | High confidence | |
| US 8,247,371 | Therapy with Clostridium Perfringens Enterotoxin to Treat Ovarian and Uterine Cancer In force · High confidence | In force | High confidence | |
| US 7,531,550 | Pseudobase Benzo[c]phenanthridines with Improved Efficacy, Stability, and Safety In force · High confidence | In force | High confidence | |
| US 8,362,028 | Pseudobase Benzo[c]phenanthridines with Improved Efficacy, Stability and Safety In force · High confidence | In force | High confidence |
Also on record, not counted in the 641: 115 patents in force now held by others · 250 patents ended · 462 applications pending · 555 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.